Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Werner Hartwig

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5071927479. Sources: OpenAlex.

Their work

Papers
27 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
108
Papers, trials and grants by year

2011: 3 papers · 2012: 6 papers · 2013: 5 papers · 2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 27

  1. Case Report: Long-term remission of metastatic pancreatic ductal adenocarcinoma after surgery and high-dose nicotinamide supplementation. First author DOI 10.3389/fonc.2026.1927317↗
  2. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  3. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  4. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  5. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  6. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  7. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.10221↗
  8. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  9. Surgical resection strategies for locally advanced pancreatic cancer. Last author DOI 10.1007/s00423-015-1318-7↗
  10. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Co-author DOI 10.1038/bjc.2015.72↗
  11. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  12. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  13. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗
  14. Improvement of surgical results for pancreatic cancer. Co-author DOI 10.1016/s1470-2045(13)70172-4↗
  15. Advanced-stage pancreatic cancer: therapy options. Co-author DOI 10.1038/nrclinonc.2013.66↗
  16. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Co-author DOI 10.1159/000354992↗
  17. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. First author DOI 10.1245/s10434-012-2762-z↗
  18. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Co-author DOI 10.1245/s10434-012-2809-1↗
  19. Prognosis of resected pancreatic cancer: is the refined resection margin status dispensable? Co-author DOI 10.1007/s00423-012-0968-y↗
  20. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. First author DOI 10.1016/j.surg.2012.05.028↗
  21. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Co-author DOI 10.1016/j.surg.2012.05.029↗
  22. Extrapancreatic malignancies in patients with pancreatic cancer: epidemiology and clinical consequences. Co-author DOI 10.1097/mpa.0b013e3182240602↗
  23. Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy) i… Co-author DOI 10.1186/1471-2407-12-112↗
  24. Growth inhibition of pancreatic cancer by experimental treatment with 4-phenylbutyrate is associated with increased expression of Connexin 43. First author DOI 10.3727/096504012x13477145152959↗
  25. Anaplastic pancreatic cancer: Presentation, surgical management, and outcome. First author DOI 10.1016/j.surg.2010.04.026↗
  26. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Co-author DOI 10.1097/sla.0b013e31821fd334↗
  27. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1097/sla.0b013e31823ac299↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Werner · 16 shared papers, 2011–2024 · strength 0.83
  2. Markus Wolfgang Büchler · 17 shared papers, 2011–2017 · strength 0.67
  3. Christiane J. Bruns · 4 shared papers, 2016–2024 · strength 0.47
  4. Thilo Hackert · 11 shared papers, 2011–2016 · strength 0.38
  5. Markus Dommach · 1 shared paper, 2026 · strength 0.32
  6. Hubert Kolb · 1 shared paper, 2026 · strength 0.32
  7. Alexander Ioannis Damanakis · 2 shared papers, 2023–2024 · strength 0.29
  8. Felix Popp · 2 shared papers, 2023–2024 · strength 0.29
  9. Alexander Quaas · 2 shared papers, 2023–2024 · strength 0.29
  10. Thomas Schmidt · 2 shared papers, 2023–2024 · strength 0.29
  11. Utz Settmacher · 2 shared papers, 2023–2024 · strength 0.29
  12. Su Ir Lyu · 2 shared papers, 2023–2024 · strength 0.29
  13. Karl Knipper · 2 shared papers, 2023–2024 · strength 0.29
  14. Bettina Rau · 2 shared papers, 2023–2024 · strength 0.29
  15. Yue Zhao · 2 shared papers, 2023–2024 · strength 0.29
  16. Oliver Strobel · 7 shared papers, 2011–2016 · strength 0.25
  17. Guralp Onur Ceyhan · 2 shared papers, 2019–2024 · strength 0.22
  18. Marc Eric Martignoni · 2 shared papers, 2017–2024 · strength 0.19
  19. Alexander Gluth · 3 shared papers, 2011–2016 · strength 0.17
  20. Helmut Friess · 2 shared papers, 2014–2024 · strength 0.17
  21. Helmut Frieß · 3 shared papers, 2014–2019 · strength 0.15
  22. John P. Neoptolemos · 4 shared papers, 2014–2017 · strength 0.14
  23. Jürgen Debus · 4 shared papers, 2012–2013 · strength 0.14
  24. Tim R. Glowka · 1 shared paper, 2024 · strength 0.14
  25. Tobias Keck · 1 shared paper, 2024 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.